TrialsgrambetaRCTs are beautiful

AUGUSTUS

2019

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

In 4,614 patients with AF and recent ACS or PCI, apixaban without aspirin reduced major or clinically relevant bleeding compared with warfarin-based triple therapy.

Result

Primary endpoint: Major or clinically relevant non-major bleeding

Apixaban vs warfarin HR 0.69; aspirin vs placebo HR 1.89 for bleeding.

Original publication
Subtopic
AF + PCI
Design
2×2 factorial RCT
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Lopes RD, et al. N Engl J Med. 2019;380(16):1509-1524.doi 10.1056/NEJMoa1817083

Discussion & critique

Established apixaban plus a P2Y12 inhibitor without aspirin as the default. Triple therapy is now limited to roughly the first week after PCI.

Discussed in podcasts